{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:32:17Z","timestamp":1769887937917,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003716","name":"Korea Basic Science Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022M3E5F3080873"],"award-info":[{"award-number":["2022M3E5F3080873"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C2010166"],"award-info":[{"award-number":["2022R1A2C2010166"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00334820"],"award-info":[{"award-number":["RS-2024-00334820"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A5A2025286"],"award-info":[{"award-number":["2018R1A5A2025286"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2021R1A6C101A442"],"award-info":[{"award-number":["2021R1A6C101A442"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bmcl.2025.130497","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:35:19Z","timestamp":1764956119000},"page":"130497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel imidazo[4,5-b]pyridine derivatives as noncovalent reversible Bruton\u2019s tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"132","author":[{"given":"Yeojeong","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoungyim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soobin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danbi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bomi","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inah","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Sang","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130497_bb0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2025.130497_bb0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmcl.2025.130497_bb0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","article-title":"Expression of Bruton\u2019s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells","volume":"152","author":"Smith","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2025.130497_bb0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bmcl.2025.130497_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmcl.2025.130497_bb0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bmcl.2025.130497_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.668131","article-title":"Targeting Bruton\u2019s tyrosine kinase in inflammatory and autoimmune pathologies","volume":"9","author":"Neys","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bmcl.2025.130497_bb0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmcl.2025.130497_bb0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/cancers14030771","article-title":"The role of Bruton\u2019s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions","volume":"14","author":"Robak","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bmcl.2025.130497_bb0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/acs.jmedchem.1c01719","article-title":"Discovery of cysteine-targeting covalent protein kinase inhibitors","volume":"65","author":"Lu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130497_bb0055","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/acschembio.3c00805","article-title":"Reversible covalent inhibition\u2013desired covalent adduct formation by mass action","volume":"19","author":"Patel","year":"2024","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130497_bb0060","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.2174\/0109298673251030231004052822","article-title":"Pirtobrutinib: first non-covalent tyrosine kinase inhibitor for treating relapsed or refractory mantle cell lymphoma in adults","author":"De","year":"2024","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2025.130497_bb0065","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.3390\/molecules26164907","article-title":"Recent advances in BTK inhibitors for the treatment of inflammatory and autoimmune diseases","volume":"26","author":"Zhang","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2025.130497_bb0070","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/acs.jmedchem.1c00926","article-title":"Discovery and preclinical characterization of BIIB091, a reversible, selective BTK inhibitor for the treatment of multiple sclerosis","volume":"65","author":"Hopkins","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130497_bb0075","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.1c01279","article-title":"Discovery of AS-1763: a potent, selective, noncovalent, and orally available inhibitor of Bruton\u2019s tyrosine kinase","volume":"64","author":"Kawahata","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130497_bb0080","doi-asserted-by":"crossref","first-page":"12526","DOI":"10.1021\/acs.jmedchem.0c00702","article-title":"Discovery of BIIB068: a selective, potent, reversible Bruton\u2019s tyrosine kinase inhibitor as an orally efficacious agent for autoimmune diseases","volume":"63","author":"Ma","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130497_bb0085","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1021\/acs.jmedchem.9b00329","article-title":"Discovery of 4-aminoquinoline-3-carboxamide derivatives as potent reversible Bruton\u2019s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis","volume":"62","author":"Yao","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130497_bb0090","doi-asserted-by":"crossref","first-page":"8917","DOI":"10.1021\/acs.jmedchem.8b01147","article-title":"Design and synthesis of novel amino-triazine analogues as selective Bruton\u2019s tyrosine kinase inhibitors for treatment of rheumatoid arthritis","volume":"61","author":"Kawahata","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130497_bb0095","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton\u2019s tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130497_bb0100","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3390\/molecules29112668","article-title":"Imidazopyridine family: versatile and promising heterocyclic skeletons for different applications","volume":"29","author":"Volpi","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2025.130497_bb0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/molecules22030399","article-title":"Pharmacological potential and synthetic approaches of imidazo[4,5-b]pyridine and imidazo[4,5-c]pyridine derivatives","volume":"22","author":"Krause","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2025.130497_bb0110","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1517\/17460441.2015.1041496","article-title":"Privileged scaffolds in lead generation","volume":"10","author":"Zhao","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130497_bb0115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.coph.2008.09.004","article-title":"Proton pump inhibitors: the beginning of the end or the end of the beginning?","volume":"8","author":"Scarpignato","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130497_bb0120","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0026-895X(25)13325-7","article-title":"The new cardiotonic agent sulmazole is an A1 adenosine receptor antagonist and functionally blocks the inhibitory regulator, Gi","volume":"33","author":"Parsons","year":"1988","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130497_bb0125","article-title":"Discovery of potent and selective reversible Bruton\u2019s tyrosine kinase inhibitors","volume":"40","author":"Qiu","year":"2021","journal-title":"Biorg Med Chem"},{"key":"10.1016\/j.bmcl.2025.130497_bb0130","doi-asserted-by":"crossref","first-page":"22726","DOI":"10.1021\/acsomega.1c03056","article-title":"Substituted benzimidazole analogues as potential \u03b1-amylase inhibitors and radical scavengers","volume":"6","author":"Akande","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmcl.2025.130497_bb0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccr.2004.09.001","article-title":"C-Src and cooperating partners in human cancer","volume":"6","author":"Ishizawar","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmcl.2025.130497_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005845","article-title":"Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets","volume":"11","author":"Laletin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bmcl.2025.130497_bb0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5045\/br.2022.2022017","article-title":"FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs","volume":"57","author":"Ahn","year":"2022","journal-title":"Blood Res"},{"key":"10.1016\/j.bmcl.2025.130497_bb0150","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3892\/br.2015.561","article-title":"Pim-1 kinase as cancer drug target: an update","volume":"4","author":"Tursynbay","year":"2016","journal-title":"Biomed Rep"},{"key":"10.1016\/j.bmcl.2025.130497_bb0155","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/pro.321","article-title":"Structures of human Bruton\u2019s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases","volume":"19","author":"Marcotte","year":"2010","journal-title":"Protein Sci"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25004068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25004068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:00:19Z","timestamp":1769835619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25004068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"alternative-id":["S0960894X25004068"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130497","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel imidazo[4,5-b]pyridine derivatives as noncovalent reversible Bruton\u2019s tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130497"}}